Disclosure of Interests: Xiaofeng Zeng: None declared, Dongbao Zhao: None declared, Sebastiao Radominski: None declared, MAURO KEISERMAN: None declared, Chang-Keun Lee: None declared, Naomi Martin Employee of: AbbVie employee and may own stock or options, Sebastian Meerwein Employee of: AbbVie employee and may own stock or options, Yunxia Sui Employee of: AbbVie employee and may own stock or options, Won Park: None declared
DOI: 10.1136/annrheumdis-2021-eular.1807

AB0261

A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES (RA-BE-REAL) – STUDY DESIGN AND BASELINE CHARACTERISTICS

R. Alten¹, G. R. Burmester², M. Matucci-Cerinic³, J. H. Salmon⁴, P. López-Romero⁵, W. Fakhouri⁵, I. De La Torre⁵, A. Gentzel-Jorczyk⁵, T. Holzkaemper⁵, B. Fautrel^{6,7}. ¹University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany; ²Charité Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; ³University of Florence, Division of Rheumatology, Florence, Italy; ⁴CHU de Reims, Traumatologie-Orthopédie, Reims, France; ⁵Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America; ⁶Sorbonne University, Department of Rheumatology, Paris, France; ⁷Pierre Louis Institute of Epidemiology and Public Health, PEPITES Team, Paris, France

Background: Baricitinib (BARI) is a JAK1-2 inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). RA-BE-REAL is a 3-year, prospective, observational study of adult RA patients (pts) evaluating adherence to treatment in clinical practice.

Objectives: To describe pt and disease characteristics of pts enrolling into RA-BE-REAL in 5 European countries.

Methods: The primary endpoint of RA-BE-REAL is time until discontinuation of initial treatment for all causes (excluding sustained clinical response) over a 24-month (M) period. Secondary endpoints include clinical and pt reported outcomes, healthcare resource utilization and treatment patterns over a 36M period. Two pt cohorts are assessed: cohort A, started treatment with BARI (2-mg or 4-mg), and cohort B, any other targeted synthetic (ts)DMARDs or biologic (b)DMARD (Fig. 1). Treatment initiation and changes are at the discretion of the pt and physician. Data is collected at baseline and at routine visits (~3M, 6M, 12M, 18M, 24M and 36M). Summaries are presented with t-test and chi-square test of independence.

Results: Between October 2018 and March 2020, 1074 adult RA pts were enrolled from France, Germany, Italy, Spain, and UK. In cohort A, 88.2% of pts are treated with BARI 4-mg. At time of enrolment pts in cohort A are more likely to commence treatment as a monotherapy as compared to pts in cohort B who are more likely to commence treatment in combination with csDMARDs ($p < 0.001$). Cohort A are more likely to be older (59.2 vs 57.0, mean years $p = 0.009$) and have higher Health Assessment Questionnaire-Disability Index (HAQ-DI) scores (1.4 vs 1.3, $p = 0.03$). A greater percentage of cohort A pts have received prior treatment with either 1 b/tsDMARD (15.3 vs 11.0%), 2 b/tsDMARD (20.2 vs 14.7%) or >2 b/tsDMARD (15.9 vs 12.9%), while cohort B are more likely to be treatment naïve (61.4 vs 48.5%). There are no significant differences in other baseline characteristics shown in Table 1.

Conclusion: There are few but potentially clinically important differences between cohorts. Pts in cohort A are more likely to be older, have a longer disease duration, have received prior b/tsDMARD treatment, and are more likely to receive treatment as a monotherapy as compared to pts in cohort B.

Figure 1. Study Design. Participants entered cohort A or B based on their treatment decision for BARI or another b/tsDMARD, pts in each cohort were with/without concomitant csDMARDs.

Table 1. Patient disposition and baseline characteristics.

	Cohort A Baricitinib (n=509)	Cohort B			Overall (n=1074)
		TNFi (n=338)	non-TNFi (n=161)	tsDMARD (n=66)	
Combination Therapy with any csDMARD	238 (46.8)	231 (40.9)	110 (19.5)	38 (6.7)	617 (57.4)
monotherapy	271 (53.2)	107 (18.9)	51 (9.0)	28 (5.0)	457 (42.6)
Values represent n (%)	Cohort A	Cohort B	p-value		Overall (n=1074)
	(n=509)	(n=565)			
Age in years	59.2 (13.2)	57.0 (13.9)	0.009		58.0 (13.6)
Disease duration in years	10.3 (9.2)	9.1 (9.8)	0.05		9.7 (9.5)
CDAI	24.1 (11.7)	23.9 (12.4)	0.75		24.0 (12.1)
Swollen joint count	5.2 (4.8)	4.7 (4.9)	0.18		4.9 (4.8)
Tender joint count	7.3 (6.1)	7.8 (6.5)	0.19		7.6 (6.3)
PhGA	5.6 (2.0)	5.5 (2.1)	0.39		5.6 (2.0)
PGA	5.9 (2.3)	5.8 (2.4)	0.49		5.9 (2.4)
Pain VAS	59.0 (23.1)	56.4 (24.3)	0.08		57.6 (23.8)
HAQ-DI	1.4 (0.7)	1.3 (0.7)	0.03		1.4 (0.7)
b/tsDMARDs treatment any time before enrolment; n (%)			<0.001*		
Naïve	247 (48.5)	347 (61.4)			594 (55.3)
1 b/tsDMARD	78 (15.3)	62 (11.0)			140 (13.0)
2 b/tsDMARDs	103 (20.2)	83 (14.7)			186 (17.3)
>2 b/tsDMARDs	81 (15.9)	73 (12.9)			154 (14.3)

Values represent mean (SD), unless otherwise stated. b/tsDMARD, biologic/targeted synthetic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; HAQ-DI, Healthy Assessment Questionnaire-Disability Index; P(h)GA, Patient's (Physician's) global assessment of disease activity; VAS, Visual analogue scale. *chi-square test of independence for comparison of b/tsDMARD treatment received before enrolment.

Acknowledgements: The authors would like to acknowledge Luke Healy for medical writing support.

Disclosure of Interests: Rieke Alten Speakers bureau: Janssen Pharmaceuticals, Eli Lilly and Company, Pfizer Inc., and Galapagos, and Gilead Sciences, Consultant of: Eli Lilly and Company, Pfizer Inc., Galapagos NV, and Gilead Sciences, Grant/research support from: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer Inc., Galapagos NV, and Gilead Sciences, Gerd Rüdiger Burmester Speakers bureau: AbbVie, Gilead Sciences, Eli Lilly and Company, and Pfizer Inc., Consultant of: AbbVie, Gilead Sciences, Eli Lilly and Company, and Pfizer Inc., Marco Matucci-Cerinic Speakers bureau: Actelion, Janssen Pharmaceuticals, MSD, Eli Lilly and Company, Biogen Inc., Grant/research support from: MSD, Actelion, Jean-Hugues Salmon: None declared, Pedro López-Romero Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, WALID FAKHOURI Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Inmaculada De La Torre Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Anja Gentzel-Jorczyk Employee of: Eli Lilly and Company, Thorsten Holzkaemper Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Bruno Fautrel Consultant of: AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Eli Lilly and Company, Medac, MSD, NORDIC Pharma, Novartis, Pfizer Inc., Roche, Sanofi-Aventis, SOBI, UCB, Grant/research support from: AbbVie, MSD, Pfizer Inc.

DOI: 10.1136/annrheumdis-2021-eular.2035

AB0262

CLINICAL EFFICACY OF SWITCHING FROM ORAL TO SUBCUTANEOUS METHOTREXATE IN MANAGEMENT OF RHEUMATOID ARTHRITIS: EXPERIENCE FROM OUT-PATIENT SETTING OF A DISTRICT GENERAL HOSPITAL IN UK

G. Ansari¹, A. Nandagudi¹, A. Bharadwaj¹. ¹Basildon Hospital Mid and South Essex NHS Foundation Trust UK, Rheumatology, Essex, United Kingdom

Background: Methotrexate (MTX) is an anchor drug in the treatment of Rheumatoid arthritis. The literature review has shown that subcutaneous (SC) methotrexate has shown better efficacy, less adverse side effects and better compliance in inflammatory arthritis. Our department modified Inflammatory arthritis pathway in 2018 where all patient with moderate or severe disease are switched from oral to SC Methotrexate injection for improved management.

Objectives: The aim of our study is to review whether switching of oral methotrexate (PO MTX) to subcutaneous methotrexate (SC MTX) helps to improve disease activity in patients with rheumatoid arthritis and avoids the need to introduce biologic therapy.

Methods: We conducted a retrospective audit of patients with rheumatoid arthritis seen between January 2018 to January 2020 recording their age, gender, diagnosis, date of MTX switch and disease activity score 6 months after switching to SC MTX. Significance of change was calculated with test of proportion/chi square test.

Results: Fifty patients were reviewed, thirty eight (76%) were female and twelve (24%) were male with age ranging between 34 - 86 years (median 61.5 years). Switching to MTX injection was done within 2 yrs of diagnosis in 21 (42%) patients, between 2-5 yrs of diagnosis in 11 (22%) patients and more than 5 yrs after diagnosis in 18 (36%) patients. The main reasons of switching were either maximum MTX dose (25mg) or intolerance to oral MTX at any dose.

After switching methotrexate, review at 6 months showed 26 patients (52%) in remission (compared to 6 at baseline) and 3 (6%) patients avoided the need to go on biologic therapy. Five patient commenced on biologic therapy between 3 and 6 months.

Table 1. Disease activity compared at Baseline and at 6 months

Disease Activity	Baseline	At 6 months
Remission <2.6	6	26 (p<0.0001)
Mild (2.6-3.19)	11	10
Mod (3.2 - 5.09)	25	9 (p<0.01)
Severe (>5.1)	8	5

Conclusion: Switching to SC Methotrexate even in patients with long duration of disease results in significant number of patients achieving remission or lower disease activity (P<0.001). This may obviate the need of biologics therapy

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.2212

AB0263

THE LEVEL OF 7-HYDROXY METHOTREXATE IN BLOOD CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS DIRECTLY CORRELATES WITH THE LEVEL OF POLYGLUTAMATES OF METHOTREXATE

G. Gridneva¹, E. Samarkina¹, S. Glukhova¹, Y. Muraviev¹, A. Kudryavtseva¹, E. Aronova¹, N. Baymeeva², V. Sygirta¹. ¹V.A. Nasonova Rheumatology Research Institute, Laboratory for the Study of Comorbid Infections and Monitoring the Safety of Drug Therapy, Moscow, Russian Federation; ²Mental Health Center, Pharmacokinetics Laboratory, Moscow, Russian Federation

Background: 7-hydroxy Methotrexate (7-hydroxy-MTX) is a phase I metabolite of MTX, which is converted by hepatic aldehyde oxidases. It is known that 7-hydroxy MTX can reduce the effectiveness of methotrexate, which is associated with increased excretion of methotrexate due to a decrease in polyglutamation and binding to enzymes [1].

Objectives: To analyze the level of 7-hydroxy-MTX in peripheral blood cells in order to study the correlation of the level of this metabolite with the level of polyglutamates of methotrexate (MTXPGs).

Methods: The prospective study included 65 patients aged 53±11 years, 50 women, 13 men, diagnosed with RA, according to the ACR/EULAR 2020 criteria, methotrexate (MTX) naive. The duration of the disease was 7,5[4;24] months. All patients were administrated MTX subcutaneously at a dose of 10-15mg/m². The visits were carried out at weeks 0, 4, 12, 24 and 36, at all visits samples were taken for the content of MTXPGs with 1,2,3 and 4 glutamate residues and 7-hydroxy MTX separately in red blood cells mass (RBC) and mononuclear cells (MO). The mononuclear fraction was isolated by layering on verografin-ficoll. All patients received folic acid at a standard dose of 5mg 24 hours after parenteral MTX administration. Samples were collected no earlier than 36 hours after MTX administration. All patients had normal renal function. Disease activity was assessed using the DAS28 index calculated by C-reactive protein.

Results: The average concentration of 7-hydroxy MTX is shown in Table 1.

Table 1. Level of 7-hydroxy MTX in erythrocytes and mononuclear cells, nmol/L, Median [25; 75 quartiles]

7-hydroxy MTX level in:	4 weeks	12 weeks	24 weeks	36 weeks
RBC	18,5[3,1;61,5]	10,2[3,6;50,8]	10,3[1,7;36,8]	7,2[0,1;25,3]
MO	0,8[0,1;15,2]	4,0[0,1;42,2]	3,5[0,1;8,1]	0,4[0,1;8,9]

The level of 7-hydroxy-MTX directly correlated with the level of MTXPGs 1-4, and summary MTXPG in both RBC and MO. Analysis of pairwise correlations according to Pearson showed that: after 4, 12 and 36 weeks, the level of 7-hydroxy-MTX did not correlate with the value of DAS28. After 24 weeks of therapy, the level

of 7-hydroxy-MTX in RBC was inversely correlated with DAS28 of the disease (p=0.043).

Conclusion: The preliminary results indicate a positive correlation between the level of 7-hydroxy-MTX and MTXPGs in RBC and MO. In this regard, the concentration of 7-hydroxy-MTX can be used as a prognostic marker for MTX therapy in the absence of opportunities in clinical centers to measure the entire line of MTXPGs in RBC and MO. Since the data obtained are somewhat at odds with the few literary sources, it is necessary to conduct further research on this fact.

REFERENCES:

- [1] Baggott JE, Morgan SL (2009) Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. *Arthritis Rheum* 60:2257–2261

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.2276

AB0264

1-YEAR RESULTS OF A NON-INVASIVE AURICULAR VAGUS NERVE STIMULATION DEVICE IN PATIENTS WITH RHEUMATOID ARTHRITIS

S. Marsal¹, H. Corominas², J. J. De Agustin¹, C. Perez-Garcia³, M. Lopez Lasanta¹, H. Borrell Paños¹, D. Reina-Sanz⁴, R. Sanmartí⁵, J. Narváez⁶, C. Franco-Jarava⁷, C. Peterfy⁸, J. A. Narvaez⁹, V. Sharma¹⁰, K. Alataris¹¹, M. C. Genovese¹², M. Baker¹³. ¹Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain; ²Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain; ³Hospital Universitari Parc Salut Mar, Rheumatology, Barcelona, Spain; ⁴Hospital Moisès Broggi, Rheumatology, Barcelona, Spain; ⁵Hospital Clínic de Barcelona, Rheumatology, Barcelona, Spain; ⁶Hospital Universitari de Bellvitge, Rheumatology, Barcelona, Spain; ⁷Hospital Universitari Vall d'Hebron, Immunology, Barcelona, Spain; ⁸Spire Sciences, NA, Boca Raton, United States of America; ⁹Clinica Diagonal, Imaging, Barcelona, Spain; ¹⁰Nēsos Corp, R&D, Redwood City, United States of America; ¹¹Nēsos Corp, NA, Redwood City, United States of America; ¹²Gilead Sciences, Clinical Development, Inflammation, Foster City, United States of America; ¹³Stanford University, Division of Immunology and Rheumatology, Stanford, United States of America

Background: Despite the clinical benefits of current pharmacological treatments for rheumatoid arthritis (RA), there remains an unmet need for alternative treatment approaches. Initial results of a 12-week proof-of-concept study of non-invasive, vagus nerve stimulation (VNS) of the auricular branch of the vagus nerve from a wearable device to treat RA showed the device to be well-tolerated with significant reductions in the DAS28-CRP and RA disease severity¹.

Objectives: This analysis presents data from the 9-month extension of the original proof-of-concept study.

Methods: Following the completion of the 12-week proof-of-concept study, responding patients (defined as achieving a reduction in DAS28-CRP of ≥1.2 from baseline and/or achievement of ACR20) were given the option to enroll in a 9-month extension study. Use of the wearable device continued daily for up to 30 minutes as in the first 12 weeks of the study. Alteration of baseline medication and addition of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and biologic DMARDs were allowed during the extension phase.

Results: 20/27 patients who completed the initial 12-week study met the enrollment criteria for the extension phase; 19 of those patients consented to participate. 4/19 patients (21%) discontinued the extension study due to lack of efficacy (1 patient after 1 month, 2 patients after 3 months, and 1 patient after 6 months in the extension); 15 patients completed the extension phase. 2/15 patients (13%) added biologic therapy to their treatment regimen. Mean DAS28-CRP reduction from baseline to the end of the extension (12 months total) in all patients completing the extension was 2.23 (95% CI: -1.60, -2.86). For patients who did and did not add biologic therapy, mean DAS28-CRP reduction was 2.98 and 2.11, respectively. Individual DAS28-CRP reductions are shown in the figure 1. Mean HAQ-DI reduction from baseline to the end of the extension in all patients was 0.70. 2 non-device related adverse events were reported in the study extension: one related to cornea transplant and one related to dysesthesia. No serious adverse events were reported during the study extension phase.

Conclusion: Benefits from the use of the wearable device were maintained over longer periods of time from the initial 12-week proof-of-concept study, with few safety concerns as no additional side effects were observed.

REFERENCES:

- [1] Marsal S et al. Non-invasive Vagus Nerve Stimulation Improves Signs and Symptoms of Rheumatoid Arthritis: Results of a Pilot Study [in press]. *The Lancet Rheumatol*, 2021